Daily Cosmetic Research Analysis
Analyzed 9 papers and selected 3 impactful papers.
Summary
A PROSPERO-registered systematic review supports radiofrequency microneedling as a safe, effective option across multiple dermatologic indications with favorable recovery, while underscoring the need for standardized device parameters. A meta-analysis suggests reduction mammoplasty is associated with meaningful improvements in female sexual function. A small veterinary case series indicates intravitreal cidofovir may palliate refractory glaucoma in silicone oil-filled eyes, preserving comfort and cosmetic globe appearance.
Research Themes
- Energy-based aesthetic dermatology and device standardization
- Quality-of-life outcomes after cosmetic surgery
- Palliative ophthalmic interventions with cosmetic considerations (veterinary)
Selected Articles
1. Effectiveness of Radiofrequency Microneedling in the Treatment of Dermatological Conditions: A Systematic Review.
This PROSPERO-registered systematic review of 41 studies (including 15 RCTs) finds radiofrequency microneedling improves atrophic acne scars, skin laxity/photoaging, and selected dyschromias with a favorable safety and recovery profile. Post-inflammatory hyperpigmentation was uncommon and self-limited; however, heterogeneity in device parameters and short follow-up limit protocol optimization.
Impact: Synthesizes scattered evidence across multiple indications and skin types, providing actionable insights for energy-based aesthetic dermatology while highlighting the need for standardized reporting.
Clinical Implications: RFMN can be considered as an alternative to fractional lasers for acne scarring and photoaging in diverse skin types with minimal downtime. Clinicians should standardize documentation of temperature, pulse width, and cooling and counsel that botulinum toxin A may outperform RFMN for primary axillary hyperhidrosis.
Key Findings
- Across 41 studies, RFMN improved atrophic acne scar scores with efficacy comparable to fractional lasers.
- For skin laxity/photoaging, RFMN improved wrinkle scales, dermal density, and submental volume, supported by histology.
- Safety profile was favorable with transient erythema/edema and infrequent, self-limited post-inflammatory hyperpigmentation.
- Patient-reported outcomes indicated high satisfaction and minimal downtime.
- Device parameter reporting (temperature, pulse width, cooling) was inconsistent, limiting cross-study comparability.
Methodological Strengths
- PROSPERO-registered protocol and use of a modified CASP checklist for quality appraisal
- Inclusion of 15 randomized controlled trials and diverse Fitzpatrick skin types
Limitations
- Heterogeneity in indications and device parameters with narrative (non-quantitative) synthesis
- Short follow-up durations and incomplete reporting of temperature, pulse width, and cooling
Future Directions: Adopt standardized outcome measures and full parameter reporting to enable meta-analysis and head-to-head device comparisons; extend follow-up to assess durability and pigmentary risks in darker skin types.
BACKGROUND: Radiofrequency microneedling (RFMN) utilizes RF energy delivered via needles to the dermis to enhance texture, reduce laxity, and improve dyschromia. However, evidence has been fragmented by indication/device heterogeneity. We evaluated clinical effectiveness, safety, and patient-reported outcomes (PROs) of RFMN across dermatological conditions. METHODS: Searches of PubMed, Google Scholar, and Semantic Scholar (January 2015-July 2025) (PROSPERO registration: CRD420251089393) were conducted, and English-language RCTs, cohort studies, case series, and reports of RFMN across skin indications were included (non-human studies excluded). A modified Critical Appraisal Skills Programme (CASP) checklist was used for quality analysis. Findings were narratively synthesized. RESULTS: Forty-one studies met the criteria (15 RCTs, 19 prospective non-randomized studies, 5 prospective cohorts, 2 case series)...
2. Sexual function following reduction mammoplasty: a systematic review and meta-analysis.
Across 13 studies (n=676), reduction mammoplasty was associated with a pooled 13.27% mean increase in female sexual function scores using standardized instruments. Although most studies reported improvement, heterogeneity and limited methodological rigor warrant cautious interpretation and further prospective research.
Impact: Quantifies patient-centered outcomes after a common aesthetic surgery and supports counseling regarding expected sexual function changes.
Clinical Implications: When counseling candidates for reduction mammoplasty, clinicians can discuss a likely improvement in sexual function while noting variability and the need for individualized expectations.
Key Findings
- Meta-analysis of 8 studies with standardized instruments showed a 13.27% increase in mean sexual function scores after reduction mammoplasty.
- Nine of 13 included studies reported significant postoperative improvement in sexual function, while four found no significant change.
- Evidence is limited by heterogeneity and generally non-randomized designs.
Methodological Strengths
- Systematic search with quantitative synthesis using a random-effects model
- Use of standardized sexual function instruments in pooled analyses
Limitations
- Predominantly observational, non-randomized designs with potential bias
- Heterogeneity in instruments, timing of assessment, and surgical techniques
Future Directions: Prospective, controlled studies with standardized timing and instruments are needed to confirm durability of sexual function improvements and identify modifiers (age, comorbidities, surgical technique).
INTRODUCTION: Reduction mammoplasty (RM) ranks as one of the most prevalent aesthetic surgical interventions globally. Since breasts are widely associated with femininity and sexual identity, many patients pursue RM with the expectation of enhancing their sexual life. OBJECTIVES: This study aims to examine the impact of RM on postoperative sexual function. METHODS: A comprehensive search was performed in electronic databases to identify articles published up to April 15, 2025. Following the removal of duplicates, 441 articles were identified to be in line with the objectives of this study. A meta-analysis was used to derive weighted pooled estimates of sexual function after RM using a random-effects model. RESULTS: After the use of eligibility criteria and exclusion of irrelevant studies, 13 articles comprising 676 participants were included in the final analysis. Nine of the included studies demonstrated a significant improvement in sexual function following RM, while 4 reported no significant changes in that regard. A meta-analysis of 8 studies that have been utilizing standardized instruments demonstrated that RM was associated with 13.27% increase in the mean score of sexual function. CONCLUSION: The findings of this systematic review revealed that female sexual function improves following RM. However, given the outlined limitations, further rigorous research is needed to confirm these results.
3. Intravitreal Cidofovir Injection for Refractory End-Stage Glaucoma and Vision Loss in Silicone Oil-Filled Eyes Following Retinal Reattachment Surgery in Dogs: Four Cases.
In four silicone oil-filled canine eyes with end-stage refractory glaucoma, a single intravitreal cidofovir injection reduced IOP to 3–7 mmHg within 2–4 weeks, controlled pain over a median 306.5-day follow-up, and maintained acceptable cosmetic globe appearance in most cases.
Impact: Provides a palliative, globe-preserving option when enucleation is declined, with quantifiable IOP and comfort outcomes in a challenging postoperative setting.
Clinical Implications: For silicone oil-filled eyes with refractory glaucoma post-retinal surgery, intravitreal cidofovir may be considered for pharmacologic ciliary body ablation to alleviate pain and lower IOP, with counseling on potential for phthisis and inflammatory sequelae.
Key Findings
- IOP dropped to 3–7 mmHg within 14–28 days after a single intravitreal cidofovir injection in all eyes.
- Pain control was maintained throughout follow-up (median 306.5 days), with owner-reported satisfaction regarding comfort and appearance.
- One case developed progressive phthisis bulbi; others maintained globe integrity and acceptable cosmetic appearance.
- Post-injection inflammation (discharge, hyperemia, aqueous flare) was common but manageable with topical therapy.
Methodological Strengths
- Objective IOP measurements with defined early post-injection assessment window
- Moderate-term follow-up with reporting of both clinical signs and owner satisfaction
Limitations
- Very small retrospective case series without controls
- Veterinary context limits generalizability; long-term safety not fully characterized
Future Directions: Prospective controlled studies comparing intravitreal cidofovir with alternative ciliary body ablation methods, with standardized pain and IOP endpoints and imaging-based structural assessments.
OBJECTIVE: To describe the clinical outcome of intravitreal cidofovir injection for palliative management of refractory end-stage glaucoma and vision loss in silicone oil-filled eyes following retinal reattachment surgery in dogs. PROCEDURES: Medical records of dogs that underwent a single intravitreal cidofovir injection for pharmacologic ciliary body ablation were retrospectively reviewed. Data collected included clinical history, intraocular pressure (IOP), post-injection ocular comfort, complications, and follow-up duration. RESULTS: Four dogs (four eyes) were included. All treated eyes demonstrated a marked reduction in IOP at the first post-injection recheck (14-28 days after injection; post-injection IOP range: 3-7 mmHg). Adequate pain control was achieved in all dogs throughout the follow-up period (median follow-up: 306.5 days; range: 40-369 days). Progressive phthisis bulbi developed in one case at long-term follow-up, while the remaining eyes maintained acceptable globe integrity and cosmetic appearance. Moderate to severe post-injection ocular discharge, conjunctival hyperemia, and aqueous flare were observed in all cases and were manageable with routine topical therapy. All owners reported satisfaction with post-injection comfort and appearance. CONCLUSIONS: A single intravitreal cidofovir injection may represent a feasible palliative option for controlling intraocular pressure and ocular pain in silicone oil-filled eyes with refractory glaucoma when enucleation is declined. Further studies are needed to better characterize long-term safety and outcomes in this clinical setting.